Peptides and peptidomimetics as therapeutic agents for Covid-19
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Covid-19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein-protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike-mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS-CoV-2.
Publication Source (Journal or Book title)
Peptide science (Hoboken, N.J.)
Dahal, A., Sonju, J. J., Kousoulas, K. G., & Jois, S. D. (2022). Peptides and peptidomimetics as therapeutic agents for Covid-19. Peptide science (Hoboken, N.J.), 114 (1), e24245. https://doi.org/10.1002/pep2.24245